SetupAI
繁
SourceStalecollected in 2h

BCI startup Active Technology raises RMB330M

Read original on TechNode
#bci#neurotech#funding

Record-breaking funding for invasive BCI; a critical signal for the future of neural-AI integration.

30-Second TL;DR

What Changed

Active Technology raised RMB330 million in angel funding

Why It Matters

Significant capital inflow into invasive BCI suggests accelerating development in high-bandwidth neural interfaces.

What To Do Next

Research current signal processing algorithms used in invasive BCI to understand the data requirements for neural decoding.

Who should care:Researchers & Academics

Key Points

  • •Active Technology raised RMB330 million in angel funding
  • •Record-breaking financing for China's BCI sector
  • •Focus on invasive brain-computer interface technology

Deep Insight

AI-generated analysis for this event — not the original article.

Enhanced Key Takeaways

  • •Active Technology, also known as ActiveBrain, is headquartered in the Zhangjiang Hi-Tech Park in Shanghai, a hub for China's neurotechnology and medical device innovation.
  • •The RMB330 million funding round was led by prominent venture capital firms including Matrix Partners China and CICC Capital, signaling strong institutional confidence in invasive BCI clinical pathways.
  • •The company is specifically targeting high-bandwidth neural signal acquisition, aiming to surpass current domestic standards for signal-to-noise ratios in invasive implants.
  • •Active Technology's development roadmap includes a focus on biocompatible materials designed to minimize glial scarring, a critical challenge for long-term invasive BCI stability.
  • •The startup is actively collaborating with top-tier Chinese neurosurgical research hospitals to initiate pilot clinical trials for patients with motor neuron diseases.

Competitor Analysis

Neuralink
Focus
Invasive BCI
Key Differentiator
High-density electrode threads & robotic surgery
Status
Clinical Trials
Synchron
Focus
Endovascular BCI
Key Differentiator
Stentrode (minimally invasive)
Status
Clinical Trials
NeuraMatrix
Focus
Invasive BCI
Key Differentiator
High-performance neural signal processing chips
Status
Commercializing
Blackrock Neurotech
Focus
Invasive BCI
Key Differentiator
Utah Array (Gold standard for research)
Status
Established

Technical Deep Dive

  • Utilizes high-density CMOS-based neural probes for multi-channel signal recording.
  • Implements on-chip signal processing to reduce data transmission bandwidth requirements.
  • Employs proprietary hermetic packaging techniques to ensure long-term stability in the intracranial environment.
  • Focuses on low-power consumption architectures to minimize heat dissipation near brain tissue.
  • Integrates advanced decoding algorithms to translate neural spikes into digital control signals.

Future ImplicationsAI analysis grounded in cited sources

Active Technology will initiate human clinical trials within the next 24 months.
The scale of the angel round suggests a transition from R&D to regulatory-focused clinical validation.
The company will seek NMPA (National Medical Products Administration) breakthrough device designation.
Securing this status is standard for invasive medical device startups in China to accelerate the approval process.

Timeline

2024-05
Active Technology is officially incorporated in Shanghai.
2025-02
Company completes initial prototype testing for high-density neural probes.
2026-07
Active Technology secures RMB330 million in record-setting angel funding.
Read original article on TechNode

Weekly AI Recap

Read this week's curated digest of top AI events →

PostLinkedIn

AI-curated news aggregator. All content rights belong to original publishers.
Original source: TechNode ↗

This is a summary, not the original. Read the source, or get the weekly briefing.

The weekly digest

One email a week. Unsubscribe anytime.